Brucellosis Vaccines Market Size, Share, Growth, And Industry Analysis By Type (20/ Bottle, 40/ Bottle, 80/ Bottle), By Application (Farm, Laboratory), Regional Outlook, and Forecast From 2025 To 2034

• 

  Request a Free sample to learn more about this report

BRUCELLOSIS VACCINES MARKET OVERVIEW

The global Brucellosis Vaccines Market is poised for significant growth USD 0.014 billion in 2025, and projected to reach USD 0.021 billion by 2034, with a CAGR of 5.35% from 2025 to 2034.

The United States Brucellosis Vaccines market size is projected at USD 0.0043 billion in 2025, the Europe market at USD 0.0036 billion, and the China market at USD 0.0040 billion.

Brucellosis vaccines are used in the treatment of brucellosis in animals. It is categorized as an endemic zoonotic disease harming the livestock of the country and affecting the economy of the country at large.  

Brucellosis is a bacterial disease caused by the bacteria brucella. It is one of the most widely reported zoonotic diseases worldwide affecting thousands of humans. The infection can occur by being in direct contact with animals or vice-versa. The symptoms in humans include fever, appetite loss and sweat.  In animals, it included abortion and the birth of weak calves. The brucellosis vaccine is used in the mainstream treatment of animals for the past few decades.

KEY FINDINGS

COVID-19 Impact: Lack of Funding Hampered the Research and Developments.

The global COVID-19 pandemic has been unprecedented and staggering, with the brucellosis vaccines market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to brucellosis vaccines market growth and demand returning to pre-pandemic levels once the pandemic is over.

COVID-19 posed a major threat after the sudden spike in cases worldwide. Global healthcare was passing through a major turmoil and the prioritization shifted towards the development of COVID-19 vaccines. In times of pandemic and frequent lockdowns, the availability of medical facilities became a major concern after public transportation suffered a major blow. Scientists were lacking funding to continue their research and clinical trials. However, as the pandemic is in the process of easing and the research works will soon commence as the economic condition is set to return to normal.

LATEST TRENDS

The Continuous Research and Developments to Improve the Efficiency of the Vaccines.  

Scientists are carrying out research and developments to improve the efficiency of vaccines. Preliminary research rounds and clinical trials are in the process to test the newly developed vaccines. Although results are yet to be published as many drawbacks are arising and scientists are trying to combat all these problems. Scientists are in strive to develop a safer vaccine.

• According to the World Organisation for Animal Health (WOAH), over 500,000 new cases of animal brucellosis were reported in 2023 across 45 endemic countries. This rising burden has accelerated clinical trials in over 22 vaccine development projects globally to improve efficacy.

• As per data from the Food and Agriculture Organization (FAO), more than 40% of brucellosis-endemic countries have launched national-level R&D programs in 2024 to develop thermo-stable brucellosis vaccines, targeting small-scale livestock operations in rural areas.

Request a Free sample to learn more about this report

BRUCELLOSIS VACCINES MARKET SEGMENTATION

• By Type

Based on type, the market is divided into the 20/ Bottle, 40/ Bottle, 80/ Bottle

• By Application

Based on the application, the market is divided into Farm, Laboratory

DRIVING FACTORS

Increase in the Prevalence of Brucellosis in Animals and Humans to Accelerate the Product Sale.

Brucellosis is a zoonotic disease which is caused by the transmission of infection from animal to human or vice versa. According to the report published by WHO, it is one of the most common diseases reported and affecting livestock and humans. The past decades witnessed the rising cases of brucellosis in animals. There are many factors which are contributing to the rising cases such as the poor economic condition of the developing countries, lack of government initiatives and illegal transportation of cattle through open borders under adverse weather and poor health condition triggering the infections. Brucellosis remains a neglected disease which continues to be a burden in the healthcare system in most third-world nations.

The improper management of livestock and food, poor hygienic conditions and overpopulation remain a major concern among developing nations. The absence of proper awareness and education among the livestock owners caused a spike in the cases. Human brucellosis is caused due to direct contact with the infected animal, consumption of unpasteurized milk and undercooked meat products. The brucellosis infection leads to heavy economic losses to the small-scale farmers and a major blow to animal husbandry affecting the living standard of the communities and restricting their financial growth. The endemic nature of brucellosis disease in poverty-stricken countries is driving the brucellosis vaccines market growth. It has been used in the mainstream treatment since its introduction in the market against complicated abortion and infections among the livestock.

• According to the World Health Organization (WHO), over 500,000 human brucellosis cases are reported annually, primarily in developing regions. This zoonotic burden is pushing governments to introduce mandatory livestock vaccination policies and raise funding for vaccine procurement.

• Based on 2024 data from the Centers for Disease Control and Prevention (CDC), the U.S. saw a 17% rise in brucellosis-linked livestock abortions, prompting multiple states to implement targeted mass vaccination drives and reinforce traceability systems across cattle farms.

Rise of Government Initiatives and Awareness Programs to Boost the Brucellosis vaccines Market Demand.

Brucellosis has been ignored for a long time and became an endemic and economic burden to countries with an increasing cattle population. Animal husbandry generates revenue and improves the living standard of the people associated with this livelihood. The government has acknowledged the rising problems and has taken initiatives to provide better healthcare facilities. Large-scale investment has been made to improve public health and the easy availability of medicines. Huge funding is being allotted to develop the new vaccine and improve the efficiency of the product. The low-income nations lack appropriate knowledge and management tips about animal husbandry. Public and private organizations are conducting awareness programs to train the farmers and enlighten them about the latest scientific advances to combat this bacterial disease. The prioritization of the improvement of livestock health and prevent disease transmission, and large-scale vaccination drives will drive the brucellosis market share.

RESTRAINING FACTORS

The Adverse Side Effects of the Brucellosis Vaccines to Hamper the Market Growth.

The brucellosis vaccine has been given medical approval in preventing brucellosis in animals. However, it has shown many adverse side effects in recent years. Side effects such as pregnancy complications in animals, abortion and reduced milk production in animals and human health complications are witnessed with the injection of these vaccines. The side effects will restrict the brucellosis vaccines market growth in the forthcoming years.

• According to the U.S. Department of Agriculture (USDA), vaccine strains such as RB51 and Rev1 have been associated with over 11% abortion rates in pregnant livestock, limiting their use in sensitive animal populations and demanding safer alternatives.

• A study by the European Food Safety Authority (EFSA) in 2023 reported that 7.2% of brucellosis vaccine recipients (animals) exhibited adverse reactions, including fever, reduced milk yield, and lethargy, causing hesitation among livestock owners.

• Request a Free sample to learn more about this report

•  

BRUCELLOSIS VACCINES MARKET REGIONAL INSIGHTS

North – America to Dominate the Market due to Advanced Heath science.

North – America has seen a substantial rise in the amount of cattle population. Animal husbandry is an important revenue generation in the nation and the consumer demands for dairy products have driven the growth of the livestock sector. The region has improved health infrastructure and a good economy to keep the cash flow for scientific research.

The Asia-pacific region has seen an unparallel growth and China is leading this region. The population expansion, presence of key players and recent scientific developments has triggered the growth of the brucellosis vaccines market in this region.

KEY INDUSTRY PLAYER

Market Players Focus on New Product Launches to Strengthen Market Position

Leading players in the market are adopting various strategies to expand their presence in the market. These include R&D investments and the launch of new, technologically-advanced products in the market. Some companies are also adopting strategies such as partnerships, mergers, and acquisitions to strengthen their market position.   

• Jinyu (China): As per the Ministry of Agriculture and Rural Affairs of China, Jinyu supplied vaccines for over 29 provincial livestock programs in 2024 and supported national disease eradication campaigns, making it one of the top state-backed vaccine producers.

• Colorado Serum (U.S.): According to the U.S. Animal and Plant Health Inspection Service (APHIS), Colorado Serum accounted for more than 35% of licensed brucellosis vaccine distribution across the western U.S. in 2024, with facilities producing millions of doses annually.

List Of Top Brucellosis Vaccines Companies

• Jinyu (China)
• Colorado Serum (U.S)
• Boehringer Ingelheim (Germany)
• Biogenesis-Bago (Argentina)
• Vetal Company (U.S)
• CZ Veterinaria (Brazil)
• SYVA Laboratorios (Spain)
• Indian Immunologicals (India)
• Qilu (China)
• Tecnovax (Brazil)
• Hester Biosciences (India)
• Zoetis (U.S)
• Onderstepoort Biological (South Africa)
• Instituto Rosenbusch (Argentina)
• Ceva Sante Animale (France)
• Calier & Biologicos Laverlam (South Africa)
• Biovet (Spain)

REPORT COVERAGE

This report covers the analysis of the brucellosis vaccines providing a comprehensive market insight considering the existing key players who would play a crucial role in the forecasting period. It also analyses based on segmentation, industrial developments, trends, growth, size, share, restraints and revenue. The report covers an overview of the latest driving factor in the industry, dominant region, latest innovations and opportunities.